Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)

SHA:688217 Revenue

Shanghai Rightongene Biotechnology had revenue of 35.86M CNY in the quarter ending March 31, 2026, a decrease of -28.72%. This brings the company's revenue in the last twelve months to 162.81M, down -28.73% year-over-year. In the year 2025, Shanghai Rightongene Biotechnology had annual revenue of 177.26M, down -26.84%.

• Revenue (ttm): 162.81M
• Revenue Growth: -28.73%
• P/S Ratio: 7.96
• Revenue / Employee: 484.56K
• Employees: 336
• Market Cap: 1.30B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	177.26M	-65.05M	-26.84%
Dec 31, 2024	242.31M	-15.91M	-6.16%
Dec 31, 2023	258.21M	-166.09M	-39.14%
Dec 31, 2022	424.30M	133.35M	45.83%
Dec 31, 2021	290.95M	6.03M	2.11%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 12, 2026

Data Sources Report a data error